Welcome, Charity Digital members. Start your free trial by 28 February for 25% off your first 3 months. Sign up

This Charity Digital offer has ended, but you can still try Hinchilla free for 4 weeks. Sign up

Cure EB

Registered charity 1158672 · since 2014cure-eb.org·International·Updated 13 November 2026

At a glance

£1M
Annual giving, year to 31 December 2024
From the Charity Commission register
Open to applications
Rolling, no deadlines · unsolicited applications welcome

Key takeaways

  • Cure EB funds research into all types of epidermolysis bullosa, with a preference for translational work and early-phase clinical trials that are close to proof of clinical concept, so a small nonprofit whose work is support or delivery rather than research is unlikely to fit.
  • Eligible applicants are clinicians, clinician-scientists and researchers in any country, and a university, hospital or recognised academic institution should endorse or sponsor the project, so a charity applying would need such an institution behind it.
  • Basic laboratory work and animal studies are generally not funded, indirect costs are not funded except up to 5% for US-based research, and projects that do not relate to a treatment of benefit to people with EB are excluded.
  • Applications are accepted on a rolling basis, starting with a Research Outline sent to the Research Team, and the funder gives no grant range, so ask the team about likely size before preparing a full application.
  • A track record in EB research is an advantage, and co-funding requests are encouraged, as they may speed up funding.

Overview

Cure EB is a charity registered with the Charity Commission for England and Wales (charity number 1158672).

Cure EB is a charity registered in England and Wales, set up by the parents of a young child with Recessive Dystrophic Epidermolysis Bullosa to fund research into effective treatments and, ultimately, a cure for all forms of EB. Its mission is simply to cure EB. It reports £20m raised and 42 projects funded, and its primary focus is translational research and early-phase clinical trials. It also funds projects targeting specific EB-related health issues and new technologies for treating all types of EB. Its annual giving is £1,047,247 on the Charity Commission register.

What they fund

Priority Areas

Cure EB funds research into all types of epidermolysis bullosa, aiming to find cures while developing treatments that provide symptom relief and improve quality of life. Its primary focus is translational research and early-phase clinical trials, including projects addressing EB-related health issues and developing technologies for treatment across all EB types. It supports gene, cell, drug and protein research, including work towards correcting or replacing genetic faults. Clinicians, clinician-scientists and researchers in any country may apply if they share its goal of curing EB. Research institutions should endorse or sponsor projects, and collaboration between groups is encouraged.

Themes

  • Translational research
  • Early-phase clinical trials
  • Gene therapy and editing
  • Cell therapy
  • Drug therapy
  • Protein therapy
  • EB cancer therapy

Geographic Focus

Any country.

What they don't fund

  • Basic laboratory research is not generally funded, including animal studies; animal studies may be funded as part of later-stage research prior to embarking on a proof-of-concept clinical trial
  • Indirect costs, except for US-based research, where up to 5% of indirect costs may be funded
  • Projects that do not relate to a treatment of local or systemic benefit to EB sufferers
  • Pre-clinical and early clinical work that does not demonstrate a pathway to future clinical application

How to apply

Potential applicants are advised to submit a Research Outline for review by the Research Team; any subsequent full application follows the application review process.

Who can apply:

  • Applications are welcome from clinicians, clinician-scientists and researchers in any country who share our goal of curing EB.
  • Cure EB welcomes applications from universities, hospitals, or recognised academic institutions in the UK or internationally. The research institution should endorse/sponsor the project.

What to send:

  • Research Outline
  • Grant Application Form

Application success factors

What the charity says:

  • It prioritises translational research projects and early-phase clinical trials.
  • It favours projects close to proof of clinical concept or with a clearly defined path towards it, and considers clinical and scientific importance.
  • A track record in EB research, or leadership in a field outside EB research, is an advantage.
  • It encourages co-funding requests; where suitable reviews and full details are shared, funding may be expedited.
  • It encourages collaboration between groups, including internationally.
  • Successful applicants must provide scientific and financial progress reports.
  • It encourages publication of research results in peer-reviewed journals.

Where they fund

Where it says it funds

Similar funders

Funders supporting work similar to Cure EB.

Five years of accounts

Income
£796,938
Expenditure
£759,771
Grants paid
£591,593
Income
£1,565,380
Expenditure
£858,839
Grants paid
£764,768
Income
£1,000,863
Expenditure
£1,122,145
Grants paid
£947,065
Income
£730,918
Expenditure
£1,552,666
Grants paid
£1,066,588
Income
£4,850,763
Expenditure
£1,410,954
Grants paid
£1,047,247

Income vs grants paid

IncomeGrants paid

Total value each financial year

YE 2020
£592k
YE 2021
£765k
YE 2022
£947k
YE 2023
£1.1M
YE 2024
£1M

In 1 of the 5 years shown, grants paid exceeded income.

  • Grants paid, all years: grants to institutions, as reported on the charity register (Part B).

Figures from the charity’s filed accounts and its register entry. The document icon links to the charity’s entry on the Charity Commission register, where its filed accounts can be found.

Sources

Other sources

  • Annual report (year to 31 December 2024)

This profile draws on the funder’s own website as well as its filed accounts.

Sources last checked on 31 October 2026.

🎯 You've done the research. Now write an application they can't refuse.

Hinchilla combines funder's specific priorities with your organisation's past successful grants and AI analysis of what reviewers want to see.

✓

Data privacy and security by default

✓

Your organisation's past successful grants and experience

✓

AI analysis of what reviewers want to see

✓

A compelling draft application in 10 minutes instead of 10 hours

Spotted something that needs correcting? Let us know

Stay Updated

Get updates on Cure EB and other funders

Subscribe
Helpful Hinchilla

Applying to Cure EB?

Hinchilla drafts your answers around this funder's priorities, using your organisation's own documents.

Start your 4-week free trial

No credit card required